Publication Date:
2006-11-16
Description:
We have previously shown, that a therapeutic platelet transfusion strategy is safe in patients after autologous peripheral stem cell transplantation(ASCT) and can reduce the number of platelet transfusions to about 50% compared with the prophylactic strategy (Wandt et al, BMT2006, 37, 387–392). To confirm these results, we started a randomised multicenter study in 2005 and present the results of the first planned interim analysis. In the prophylactic platelet transfusion arm (p) transfusions were given to patients if the morning platelet count was 〈 10/nl, while in the therapeutic transfusion arm (t) clinically stable patients (no sepsis or systemic inflammatory response syndrome II° or III° (SIRS), no invasive Aspergillosis or infection with Stenotrophomonas maltophilia) received platelet transfusions only in the case of clinically relevant bleeding. Apheresis platelets were recommended, but pooled platelet units were allowed as well. We now analysed the first 92 patients, 45 patients with a prophylactic and 47 patients with a therapeutic transfusion strategy. Both groups were well balanced according to age, gender, diagnosis and conditioning regimens. Median days of thrombocytopenia 〈 20/nl were 4 (0–14) in the prophylactic and 4 (0–20) in the therapeutic arm. The corresponding days regarding platelets below 10/nl were 1(p) (0–5) and 2(t) (0–14), respectively. The total number of days with thrombocytopenia
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink